Major Depressive Disorder

What is the hidden mental health struggles of affluent youth? In this Tales From the Clinic article, we reveal how wealth can contribute to anxiety, depression, and substance misuse.

Combination therapy of TMS and ketamine could enhance brain perfusion and neuroplasticity.

NRx Pharmaceuticals secures FDA fee waiver for NRX-100, a preservative-free ketamine aimed at treating suicidal depression, enhancing accessibility for patients.

Check out the pipeline updates from April!

Discover how deep brain stimulation, a breakthrough treatment, offers hope for patients with treatment-resistant depression.

In this CME article, explore the complexities of Parkinson disease, focusing on neuropsychiatric symptoms, their prevalence, and effective treatment strategies for improved patient care.

Transneural Therapeutics launches innovative neuroplastogens to revolutionize treatment for neuropsychiatric diseases, promising safer, effective alternatives to psychedelics.

Cybin partners with Osmind to enhance mental health treatment access, focusing on innovative therapies for depression and anxiety disorders.

The first patient has been dosed in MindMed’s phase 3 Emerge study evaluating the efficacy of MM120 ODT.

The Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) for treatment-resistant major depressive disorder has now demonstrated promise for reducing depressive symptoms of bipolar I disorder in an open-label feasibility and safety trial.

Patients with treatment resistant late-life depression are more likely to respond to antidepressants when sleep is sufficient or has improved.

Cognitive symptoms affect between 85% and 94% of patients with major depressive disorder. Despite this prevalence, cognitive dysfunction often remains undertreated and inadequately addressed in routine clinical practice.

Celebrate our 40th anniversary with Gustavo Alva, MD, FAPA, our Mood Disorders Section Editor.

Ketamine or ECT? A new study reveals which works best for severe depression—depending on the patient and setting.

Alzamend announced a late 2025 initiation for the phase 2 clinical study of AL001, a novel lithium-delivery system for the treatment of patients with major depressive disorder.

A new transcranial direct current stimulation device received approval from the FDA for an investigational device exemption, prompting a phase 3 trial.

Rejoyn, a new app being prescribed as a depression treatment, is an emotional face memory task designed to correct abnormal neural circuits.

Dennis S. Charney, MD, discussed the importance of trying and risking failure when studying new potential treatments, as well as the future of treating depression.

Discover key insights from February’s Special Report on child and adolescent psychiatry, exploring overlooked diagnoses, new research, and the complex impact of social media on youth mental health.

Dennis S. Charney, MD, discussed the discovery of ketamine as a rapid-acting treatment for depression, its journey from skepticism to FDA approval, and its impact on mental health care.

Here are highlights from this week in Psychiatric Times, including updates on the BHV-7000 for bipolar disorder trial and a new study on physician suicide rates.

A recent study found that ketamine and transcranial magnetic stimulation show promise in treating treatment-resistant depression in older adults.

BLP-003, currently being evaluated for treatment-resistant depression and alcohol use disorder, today announced their global phase 2b clinical trial has completed patient enrollment.

Celebrate Psychiatric Times’ 40th anniversary with a look back at some of our previous covers.

Learn more about recent research into adolescent mental health, including a pilot study testing the use of short-term trauma stabilization techniques with escitalopram.

Celebrate Psychiatric Times’ 40th anniversary with a look back at some of our previous covers.

After a lot of recent positive news for SPN-820, a recent phase 2b study shows the novel antidepressant failed to demonstrate a statistically significant improvement on the primary endpoint of change from baseline.

What are the top 6 disappointing psychopharmacological updates from the past year? We rank the top 6.

Catch up on coverage from the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update.